Business Description
Genetic Analysis AS
ISIN : NO0010692130
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.55 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.03 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17 | |||||
3-Year EBITDA Growth Rate | 9.2 | |||||
3-Year EPS without NRI Growth Rate | 9.4 | |||||
3-Year FCF Growth Rate | 0.1 | |||||
3-Year Book Growth Rate | -23.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.35 | |||||
9-Day RSI | 49.74 | |||||
14-Day RSI | 47.71 | |||||
6-1 Month Momentum % | 45.76 | |||||
12-1 Month Momentum % | -21.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.79 | |||||
Quick Ratio | 1.69 | |||||
Cash Ratio | 0.61 | |||||
Days Inventory | 112.29 | |||||
Days Sales Outstanding | 58.05 | |||||
Days Payable | 321.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15 | |||||
Shareholder Yield % | -12.84 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 68.26 | |||||
Operating Margin % | -181.94 | |||||
Net Margin % | -153.45 | |||||
FCF Margin % | -129.55 | |||||
ROE % | -75.21 | |||||
ROA % | -46 | |||||
ROIC % | -76.33 | |||||
3-Year ROIIC % | -220.55 | |||||
ROC (Joel Greenblatt) % | -337.55 | |||||
ROCE % | -61.37 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.95 | |||||
PB Ratio | 1.2 | |||||
Price-to-Tangible-Book | 3.13 | |||||
EV-to-EBIT | -1.65 | |||||
EV-to-Forward-EBIT | -1.56 | |||||
EV-to-EBITDA | -2.2 | |||||
EV-to-Revenue | 2.45 | |||||
EV-to-Forward-Revenue | 0.66 | |||||
EV-to-FCF | -1.87 | |||||
Price-to-Net-Current-Asset-Value | 6.82 | |||||
Earnings Yield (Greenblatt) % | -60.85 | |||||
FCF Yield % | -49.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Genetic Analysis AS Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 14.08 | ||
EPS (TTM) (kr) | -0.594 | ||
Beta | 0 | ||
Volatility % | 63.4 | ||
14-Day RSI | 47.71 | ||
14-Day ATR (kr) | 0.039661 | ||
20-Day SMA (kr) | 0.7486 | ||
12-1 Month Momentum % | -21.16 | ||
52-Week Range (kr) | 0.27 - 1.75 | ||
Shares Outstanding (Mil) | 49.38 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Genetic Analysis AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Genetic Analysis AS Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Genetic Analysis AS Frequently Asked Questions
What is Genetic Analysis AS(XSAT:GEAN)'s stock price today?
When is next earnings date of Genetic Analysis AS(XSAT:GEAN)?
Does Genetic Analysis AS(XSAT:GEAN) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |